Endothel Pharma ApS: Financial statements 2023
CVR: 37988936
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Endothel Pharma ApS (CVR 37988936) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -57,141 and a net result of DKK -91,000 compared with DKK -76,253 the year before. Equity in the 2023 report amounted to DKK -294,322.
- Gross Profit
- DKK -57,141
- Profit/Loss
- DKK -91,000
- Equity
- DKK -294,322
- Total Assets
- DKK 558,742
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -57 t. | -91 t. | -294 t. | 0 |
| 2022 | - | -48 t. | -76 t. | -203 t. | 0 |
| 2021 | - | -25 t. | -47 t. | -127 t. | 0 |
| 2020 | - | -13 t. | -29 t. | -80 t. | 0 |
| 2019 | - | -23 t. | -36 t. | -52 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Endothel Pharma ApS has published its annual report for 2022. Gross profit came to DKK -47,868, and the net result was DKK -76,253.
About Endothel Pharma ApS
Endothel Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Rikke Stine Friis Fléron. The company is owned by Bo Jesper Hansen, Pär Ingemar Johansson and Trial-Lab Holding AB. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -43,536 and a net result of DKK -87,006 compared with DKK -81,618 the year before. Equity in the 2025 report amounted to DKK -462,946.